Artemisinin Antimalarial Drugs Market Size & Share 2024 to 2032

Artemisinin Antimalarial Drugs Market Size

Artemisinin Antimalarial Drugs Market was valued at USD 672.2 million in 2023 and is anticipated to grow at a CAGR of 4.2% between 2024 – 2032. The rising incidence of malaria, particularly in tropical and subtropical regions, has increased the demand for effective treatments.

For instance, as per the CDC, in 2022, an estimated 249 million malaria cases occurred globally, leading to 608,000 malaria deaths in a single year. Such high incidence of malaria cases increases the demand for effective treatments, thereby driving the growth of artemisinin antimalarial drugs market.
 

Additionally, the emergence of artemisinin-based combination therapies (ACTs) as a gold standard for malaria treatment has significantly contributed to market expansion. Moreover, ongoing research and development efforts aimed at enhancing the efficacy and safety profiles of these drugs coupled with advancements in malaria diagnostics further boost market growth. The global focus on malaria eradication and the support from international organizations, including the World Health Organization, in funding and promoting antimalarial programs also play a crucial role. Furthermore, the growing awareness about the importance of early diagnosis and treatment of malaria supports the demand for artemisinin-based therapies, driving the market forward.
 

Artemisinin antimalarial drugs are a class of medications derived from the plant Artemisia Annua, commonly known as sweet wormwood. These drugs are primarily used to treat malaria, particularly in cases caused by Plasmodium falciparum. Artemisinin-based treatments are known for their rapid action in reducing parasite load and alleviating symptoms. The most common form of these treatments are artemisinin-based combination therapies (ACTs), which combine artemisinin derivatives with other antimalarial drugs to enhance efficacy and reduce the risk of drug resistance.
 

Artemisinin Antimalarial Drugs Market Trends

• The high prevalence of malaria is a significant driver of the market.
   
• Malaria remains a major global health challenge, particularly in regions with endemic transmission, such as sub-Saharan Africa, Southeast Asia, and parts of South America.
   
• For instance, in 2022, there were an estimated 233 million cases and 608,000 deaths in the WHO African Region, accounting for about 94% of global malaria cases. Asia ranks second to Africa in terms of malaria burden. In 2022, the region reported approximately 16 million cases and 45,600 deaths. Major contributors to the malaria burden in Asia include India, Indonesia, Myanmar, and Pakistan, which collectively account for over 85% of reported cases.
   
• This persistent burden of malaria has led to a continuous demand for effective treatments, with artemisinin-based combination therapies (ACTs) being the cornerstone of malaria treatment due to their high efficacy against Plasmodium falciparum, the most dangerous malaria parasite.
   
• This sustained demand for ACTs fuels market growth, as healthcare systems and organizations strive to reduce malaria incidence and mortality.
   
• Moreover, efforts to combat malaria, including international initiatives and funding for drug development, further bolster the market by ensuring a steady supply of these critical medications.
   

Artemisinin Antimalarial Drugs Market Analysis

Based on the malaria type, the artemisinin antimalarial drugs industry is categorized into Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and Plasmodium knowlesi. The Plasmodium falciparum segment dominated the market with USD 553.8 million in 2023.
 

• Plasmodium falciparum, the most virulent of the malaria-causing parasites, holds a significant market share in the industry due to its high prevalence and the severity of the infections it causes.
   
• Artemisinin-based combination therapies (ACTs) are the frontline treatment for P. falciparum malaria, given their effectiveness in rapidly clearing the parasite from the bloodstream and reducing mortality.
   
• The high burden of P. falciparum malaria, particularly in regions of Sub-Saharan Africa and Southeast Asia, drives the demand for these treatments.
   
• Consequently, the market for artemisinin antimalarial drugs is heavily influenced by the need to combat P. falciparum, reinforcing its dominant position within the therapeutic landscape.

Learn more about the key segments shaping this market

Download Free PDF

Based on product, the artemisinin antimalarial drugs market is segmented into antimalarial injections and antimalarial tablets. The antimalarial tablets segment is dominated the market holding the highest market share of 80.5% in 2023.
 

• High market share of artemisinin antimalarial tablets can be attributed to their widespread use and effectiveness in treating malaria.
   
• These tablets, often formulated with artemisinin derivatives such as artemether and lumefantrine, are preferred for their potent antimalarial properties and convenience of administration.
   
• Additionally, the integration of antimalarial tablets into national treatment guidelines and their availability in both public health systems and private markets contribute to their dominant position in the market.
   

Based on the type, the artemisinin antimalarial drugs market is segmented into monotherapy and combination therapy. The combination therapy segment is projected to reach USD 660.7 million by 2032.
 

• Combination therapy holds a significant market share in the artemisinin antimalarial drugs industry due to its enhanced efficacy in treating and preventing malaria. This therapeutic approach, which combines artemisinin-based compounds with other antimalarial agents, helps to address drug resistance issues and improve treatment outcomes.
   
• By leveraging the synergistic effects of multiple drugs, combination therapy not only increases the overall efficacy of malaria treatment but also reduces the likelihood of resistance developing.
   
• This strategy aligns with global health guidelines and is supported by extensive clinical evidence, contributing to its dominant position in the market.

Middle East & Africa market was valued at USD 231.5 million in 2023 and is expected to witness growth at a CAGR of 4.1% between 2024 – 2032.
 

• The Middle East and Africa (MEA) region holds a significant market share in the artemisinin antimalarial drugs market due to the high prevalence of malaria in several countries within the region.
   
• The ongoing efforts to combat malaria through various health initiatives and the strong support from both governmental and non-governmental organizations contribute to the robust market presence.
   
• Additionally, the increasing investments in healthcare infrastructure, rising awareness about malaria prevention, and the growing availability of artemisinin-based combination therapies (ACTs) have bolstered the region’s market share.
   
• These factors, combined with the region's strategic focus on improving treatment outcomes and access to antimalarial drugs, underscore its crucial role in the global market.
   

Asia Pacific region accounted for the second largest share of 26.7% in 2023. 
 

• Countries such as India, Pakistan, Indonesia, and others suffer from a high burden of malaria cases in the region. India is known for the world's third-highest malaria burden. 
   
• Similarly, as per the World Malaria Report, in 2022, India accounted for 66% of malaria cases in the WHO South-East Asia region.
   
• Additionally, several initiatives taken by public organizations in the APAC countries to reduce the burden of malaria and provide proper treatment are expected to boost the market in Asia Pacific. 
   
• For instance, the government of India developed a National Strategic Plan (NSP, 2017-2022) and National Framework for Malaria Elimination (2016-2030) to eradicate malaria disease by providing treatment at a low cost. 
   
• Such initiatives are likely to support the market in Asia Pacific in the forecast.
   

Latin American region presents significant growth potential in the artemisinin antimalarial drugs market due to a combination of factors. 
 

• The increasing incidence of malaria in certain areas, coupled with the growing awareness and implementation of malaria control programs, is driving demand for effective antimalarial treatments. 
   
• Moreover, the region's improving healthcare infrastructure and increased investment in pharmaceutical research and development are contributing to the expansion of market opportunities. 
   
• Additionally, the rising focus on improving access to essential medicines in underserved areas supports the demand for artemisinin-based therapies, positioning Latin America as a promising market for growth in the coming years.
   

Artemisinin Antimalarial Drugs Market Share

The competitive landscape of the artemisinin antimalarial drugs industry is characterized by a diverse mix of pharmaceutical companies and research institutions striving to innovate and expand their market presence. Key players in this sector include pharmaceutical giants like Novartis and Sanofi, which have established themselves as leading suppliers of artemisinin-based combination therapies (ACTs). These companies leverage their extensive distribution networks and substantial R&D investments to maintain a competitive edge. 
 

Additionally, smaller biotech firms and emerging players are actively involved in developing new formulations and improving the efficacy of existing treatments. Strategic collaborations, partnerships, and ongoing research into novel drug combinations and delivery methods are pivotal in shaping the competitive dynamics and driving advancements in the market.
 

Artemisinin Antimalarial Drugs Market Companies

Few of the prominent players operating in industry include:

• AdvaCare Pharma USA LLC
• Calyx Chemicals and Pharmaceuticals Ltd.
• Cipla Limited
• Guilin Pharmaceutical Co., Ltd.
• Ipca Laboratories Ltd.
• KPC Pharmaceuticals, Inc.
• Novartis AG
• Rusan Pharma Ltd.
• Sanofi S.A.
• Shin Poong Pharmaceutical Co., Ltd.
   

Artemisinin Antimalarial Drugs Industry News:

• In April 2024, Novartis and Medicines for Malaria Venture (MMV) announced promising results from the CALINA Phase II/III study evaluating a new formulation of Coartem as a treatment for infants under 11 lbs. with malaria. The successful development of a Coartem formulation for infants under 5 kg addresses a critical unmet need in malaria treatment. This opens up a new market segment, potentially increasing sales and market share in the pediatric segment of malaria treatments.
   

The artemisinin antimalarial drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Malaria Type

• Plasmodium falciparum
• Plasmodium vivax
• Plasmodium ovale
• Plasmodium malariae
• Plasmodium knowlesi

Market, By Product

• Antimalarial injections
• Antimalarial tablets

Market, By Type

• Monotherapy
• Combination therapy

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa